Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
The Lancet. Oncology
|
August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi, Li Zhang, Xiaoqing Liu, et al.
BMC Medicine
|
February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
The Oncologist
|
June 9, 2021
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)
Yihebali Chi, Yongqian Shu, Yi Ba, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai, Yueyin Pan, Jianhua Shi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
Yuankai Shi, Baolan Li, Lin Wu, et al.
Future Oncology (London, England)
|
December 4, 2024
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
Zefei Jiang, Quchang Ouyang, Tao Sun, et al.
Cancer Communications (London, England)
|
July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)
Shun Lu, Xiaorong Dong, Hong Jian, et al.
Nature Medicine
|
January 8, 2024
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Zefei Jiang, Quchang Ouyang, Tao Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
Shun Lu, Xiaorong Dong, Hong Jian, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
The Lancet. Oncology
|
August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi, Li Zhang, Xiaoqing Liu, et al.
BMC Medicine
|
February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
Yuankai Shi, Jianhua Chen, Helong Zhang, et al.
The Oncologist
|
June 9, 2021
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)
Yihebali Chi, Yongqian Shu, Yi Ba, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 29, 2021
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai, Yueyin Pan, Jianhua Shi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
Yuankai Shi, Baolan Li, Lin Wu, et al.
Future Oncology (London, England)
|
December 4, 2024
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
Zefei Jiang, Quchang Ouyang, Tao Sun, et al.
Cancer Communications (London, England)
|
July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)
Shun Lu, Xiaorong Dong, Hong Jian, et al.
Nature Medicine
|
January 8, 2024
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Zefei Jiang, Quchang Ouyang, Tao Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
Shun Lu, Xiaorong Dong, Hong Jian, et al.
Page
of 11